Health & Beauty

The recently released "Tianjin Municipal Action Plan for Strengthening the City of Traditional Chinese Medicine (2022-2025)" for comments pointed out that it is necessary to promote the high-quality development of traditional Chinese medicine and the industry, and build a strong city of traditional Chinese medicine. Anhui issued the "Anhui Province Action Plan for Promoting the Revitalization and Development of Traditional Chinese Medicine (2022-2024)", striving to achieve a total output value of 400 billion yuan in the province's traditional Chinese medicine industry and the entire industry chain of traditional Chinese medicine health services in three years, and the industry scale and competitiveness will enter the country's No. 1 A square.

At present, the traditional Chinese medicine industry is ushering in a period of full-speed development, and the entire industry chain continues to "supplement, extend, and strengthen the chain" to aggregate resource elements. Industry insiders believe that the high-quality development of traditional Chinese medicine has become the consensus of the industry, but from the perspective of the industry itself, compared with chemical drugs and innovative pharmaceutical equipment, the innovation of the traditional Chinese medicine industry is still insufficient, which will become the focus of future efforts in various regions.

Accelerate the layout of the whole industry chain in many places

What is different from the previous ones is that this round of action plans issued in many places has no longer positioned the development of the traditional Chinese medicine industry as simply as adding traditional Chinese medicine hospitals and beds.

According to the Tianjin TCM City Action Plan, by 2025, Tianjin will fully build a TCM industrial cluster that matches the functional orientation of Tianjin's socialist modern metropolis, and the pillar status of the TCM industry will be further strengthened. Vigorously develop the traditional Chinese medicine industry chain. Promote the deep integration of the innovation chain of the traditional Chinese medicine industry chain, forge the "long board" of the industrial chain, enhance the core competitiveness of the traditional Chinese medicine industry, and promote the high-quality development of the traditional Chinese medicine industry. Support the construction of traditional Chinese medicine industrial parks, support the construction of traditional Chinese medicine health industrial parks in Jinghai District, and support the planning and construction of Beichen Beijing-Tianjin Medicine Valley in Beichen District. Support the establishment of a Beijing-Tianjin-Hebei Chinese medicine industry demonstration base in the China-Japan (Tianjin) Health Industry Development Cooperation Demonstration Zone.

Anhui Province's Action Plan for Promoting the Revitalization and Development of Traditional Chinese Medicine pointed out that the institutional and institutional barriers that restrict the high-quality development of the traditional Chinese medicine industry should be removed, the entire industry chain should promote the revitalization and development of traditional Chinese medicine, and use new technologies and models such as big data, artificial intelligence, and biology to empower Traditional Chinese medicine planting and breeding, production and processing, trade services, research and development innovation, talent training, and promote the modernization and transformation of traditional Chinese medicine.

Anhui strives to build a traditional Chinese medicine service system with sound network, complete functions, obvious characteristics, efficient governance, covering the whole life cycle of the whole people, and cultivate a group of famous Chinese medicine hospitals, Famous doctors, famous departments, famous Chinese medicine enterprises, and famous medicines, to create more than 30 large varieties of traditional Chinese medicine with an output value of over 100 million yuan, and more than 10 enterprises with a scale of over 1 billion yuan.

Among them, Bozhou Modern Traditional Chinese Medicine Province is a major emerging industry base. By 2024, the industrial output value of the base will reach more than 50 billion yuan, and the output value of the entire industry chain will exceed 200 billion yuan. Accelerate the construction of Dabie Mountain's "Western Yam Warehouse" and other industrial agglomeration areas, forming a good momentum of competitive development. By 2024, build more than 5 traditional Chinese medicine industry clusters with distinctive characteristics and strong industrial competitiveness.

Specifically, Anhui established a life and health industry themed parent fund to support enterprises, city and county people's governments, and social capital to set up sub-funds for the development of traditional Chinese medicine industry by way of equity participation, and to support the development of leading traditional Chinese medicine enterprises and the construction of major projects in a market-oriented way. Implement the cultivation plan for backbone enterprises of traditional Chinese medicine, and strengthen precise guidance and policy support. Support qualified enterprises to connect with multi-level capital market for listing and listing. Guide leading enterprises to form a traditional Chinese medicine industry group integrating R&D, production and sales, and build an influential Anhui medicine brand in the country.

Innovation becomes the key word for high-quality development

A few days ago, the "14th Five-Year Plan for National Health" issued by the State Council proposed to promote the inheritance, innovation and development of traditional Chinese medicine, give full play to the role of traditional Chinese medicine in health services, and consolidate the foundation for high-quality development of traditional Chinese medicine.

Industry insiders pointed out that innovation is the key to the high-quality development of the Chinese medicine industry.

Taking Tianjin as an example, the city has comprehensively built a national Chinese medicine (acupuncture) medical center. Focusing on the inheritance, innovation, promotion and application of acupuncture and moxibustion technology, we will improve the facilities and equipment of traditional Chinese medicine scientific research platforms, carry out research on core technologies, and solve the problem of "one step at a time". Through the construction of the National Traditional Chinese Medicine (Acupuncture) Medical Center, a high-level, international and open clinical research transformation platform, an innovative technology incubation base, a training base for traditional Chinese medicine talents, a data collection platform and a traditional Chinese medicine industry cluster will be built. Relax the innovative application policy of the National Traditional Chinese Medicine (Acupuncture) Medical Center, and encourage the National Traditional Chinese Medicine (Acupuncture) Medical Center to conduct clinical trials. Support the National Traditional Chinese Medicine (Acupuncture) Medical Center to conduct pilot tests in terms of medical service prices, medical insurance payment, personnel compensation system, and benefit distribution.

Anhui is speeding up the establishment of Huatuo Institute of Traditional Chinese Medicine, Xin'an Medical Research Institute and Dabieshan Institute of Traditional Chinese Medicine, and the listing will be completed within 2022. Strive to add about 10 provincial-level innovation platforms within 3 years, actively strive to create national-level innovation platforms, and provide support in accordance with relevant policies of provincial-level innovation platforms. Build a public service platform for the traditional Chinese medicine industry that integrates key common technology research and development, pilot-scale maturation, inspection and testing and other functions according to the method of competitive selection. For the assessed industrial public service projects, 20% of the investment in fixed assets (excluding land investment) will be subsidized, and the provincial maximum subsidy will be 5 million yuan.

In terms of new drug innovation in traditional Chinese medicine, Anhui will promote the deep integration of traditional Chinese medicine with big data technology and modern clinical research, accelerate the development of modern traditional Chinese medicine for anti-virus, cardiovascular and cerebrovascular diseases, anti-tumor, diabetes, etc., and improve the directional extraction and separation of active ingredients of traditional Chinese medicine. and other key technologies. Accelerate the development and production of new TCM preparations, biochips, kits and other products that can be used for TCM syndrome diagnosis, TCM intervention disease activity determination, or efficacy evaluation. In addition, Anhui subsidizes 20% of the cost of preclinical research and clinical trials for innovative Chinese medicines, improved new Chinese medicines, and ancient classical and famous Chinese medicine compound preparations, with a maximum provincial subsidy of 5 million yuan for a single project.

The development of traditional Chinese medicine and equipment has accelerated significantly

Some analysts pointed out that the current development of Chinese medicine in my country is still faced with practical problems such as weak basic research, lack of talents, and insufficient innovation ability. However, with the implementation of a series of policies and plans in recent years, innovation in the field of traditional Chinese medicine and its medicinal devices has begun to accelerate.

According to public information, in 2021, the Drug Evaluation Center of the State Drug Administration will accept 1,886 applications for registration of innovative drugs (998 varieties), a year-on-year increase of 76.10%; among them, 54 innovative traditional Chinese medicines (51 varieties), a year-on-year increase of 134.78% , higher than the growth rate of innovative chemical drugs and innovative biological products.

Judging from the specific review and conclusion, 34 applications for clinical trials of new Chinese medicines will be approved in 2021, a year-on-year increase of 21.43%; among the new Chinese medicines approved for marketing approval, 14 are recommended to be approved, a year-on-year increase of 250.00%, a new high in five years. 34 clinical trials of traditional Chinese medicines have been approved, involving 13 indication fields such as digestion, respiration and gynecology. Among the traditional Chinese medicines proposed for approval, there are many drugs for respiratory tumors, neuropsychiatry, and orthopedics, accounting for 71.43% of the total approved amount.

"The Center for Drug Evaluation will include new traditional Chinese medicines with obvious clinical value into the priority review and approval process. Go all out to speed up the review of applications for marketing authorization of traditional Chinese medicines, and give full play to the unique advantages of traditional Chinese medicines in disease prevention and treatment." State Drug Administration Drug Review The relevant person in charge of the center said that from 2019 to 2021, from 2019 to 2021, the number of clinical trial applications and proposed approvals of traditional Chinese medicine innovative drugs, as well as new drug marketing applications and proposed approvals, have shown a trend of increasing year by year. In the next step, in accordance with the principles of inheriting the essence, maintaining integrity and innovation, and developing with high quality, we will deeply study and summarize the practical experience of traditional Chinese medicine review and approval and the reform results of the drug review and approval system. Combine the characteristics of traditional Chinese medicine and the actual situation of research and development, and actively study the adjustment of traditional Chinese medicine registration classification. .

The person said that based on the traditional Chinese medicine registration review evidence system that combines traditional Chinese medicine theory, human experience, and clinical trials, the review standards and guiding principles are formulated. Select 3 specific indications of malignant tumor, chronic gastritis, and gastroesophageal reflux disease as breakthrough points, introduce new tools and new methods such as real-world research, and work with authoritative experts in the field of TCM clinical related indications to evaluate the clinical efficacy that conforms to the characteristics of TCM Technical requirements are researched and guiding principles are gradually formed.

In addition to the innovation of traditional Chinese medicine, the innovation of traditional Chinese medicine equipment is also advancing. In recent years, the number of effective TCM products in my country has shown a significant upward trend. According to the statistics of Zhongcheng Digital, the number of effective registrations of TCM products has increased from 1,154 in 2018 to 2,512 in 2021, with a compound growth rate of 29.6%. The purchase amount of traditional Chinese medicine equipment in public hospitals increased from 65.44 million yuan in 2019 to 78.44 million yuan in 2021.

An industry insider said that the TCM medical device market is relatively small, companies are reluctant to take too many risks in research and development, and the TCM industry has low willingness to actively develop innovative devices; Insufficient output of technology and R&D talents. In addition, due to the lack of in-depth industry-university-research cooperation and the lack of ways to transform scientific and technological achievements, it is difficult for the latest technologies of scientific research institutes to be transformed into realizable products.

"But now, the industry demand has changed significantly, especially under the big health system, the demand for consumer TCM devices has grown rapidly, which will further promote the transformation and upgrading of the industry, and develop high value-added, high-tech TCM medical device products." said the above.